Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

• Sponsor: Hunan Province Tumor Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT05055999
• Collaborator: (none)
• Enrollment: 60
• Location: 1
• Actual Duration (Months): 29
• Patients Per Site Per Month: 2.1

Study Details

Study Description

Brief Summary

The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Extensive Stage Small Cell Lung Cancer	Drug: First line EC/EP+Atezolizumab

Study Design

• Study Type: Observational
• Actual Enrollment: 60 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
• Actual Study Start Date: Apr 1, 2019
• Actual Primary Completion Date: Jul 1, 2021
• Actual Study Completion Date: Sep 1, 2021

Outcome Measures

Primary Outcome Measures

1. PFS [April 2019- July 2021]

   Progression free survival

2. OS [April 2019- July 2021]

   Overall survival

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hunan Cancer Hospital	Changsha	Hunan	China	410013

Sponsors and Collaborators

• Hunan Province Tumor Hospital

Investigators

• Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Yongchang Zhang, Director, Head of Medical Oncology, Principal Investigator, Clinical Professor, Hunan Province Tumor Hospital
• ClinicalTrials.gov Identifier: NCT05055999
• Other Study ID Numbers: MATCH
• First Posted: Sep 24, 2021
• Last Update Posted: Jan 25, 2022
• Last Verified: Apr 1, 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Lung Neoplasms; Small Cell Lung Carcinoma; Atezolizumab

Study Results

No Results Posted as of Jan 25, 2022